1. Home
  2. CAPR vs LOCO Comparison

CAPR vs LOCO Comparison

Compare CAPR & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • LOCO
  • Stock Information
  • Founded
  • CAPR 2005
  • LOCO 1980
  • Country
  • CAPR United States
  • LOCO United States
  • Employees
  • CAPR N/A
  • LOCO N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • LOCO Restaurants
  • Sector
  • CAPR Health Care
  • LOCO Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • LOCO Nasdaq
  • Market Cap
  • CAPR 324.6M
  • LOCO 323.7M
  • IPO Year
  • CAPR N/A
  • LOCO 2014
  • Fundamental
  • Price
  • CAPR $7.62
  • LOCO $9.41
  • Analyst Decision
  • CAPR Strong Buy
  • LOCO Buy
  • Analyst Count
  • CAPR 7
  • LOCO 2
  • Target Price
  • CAPR $24.71
  • LOCO $18.00
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • LOCO 181.5K
  • Earning Date
  • CAPR 11-12-2025
  • LOCO 10-30-2025
  • Dividend Yield
  • CAPR N/A
  • LOCO N/A
  • EPS Growth
  • CAPR N/A
  • LOCO N/A
  • EPS
  • CAPR N/A
  • LOCO 0.85
  • Revenue
  • CAPR $13,392,150.00
  • LOCO $479,690,000.00
  • Revenue This Year
  • CAPR N/A
  • LOCO $6.34
  • Revenue Next Year
  • CAPR $7,894.07
  • LOCO $1.52
  • P/E Ratio
  • CAPR N/A
  • LOCO $10.94
  • Revenue Growth
  • CAPR N/A
  • LOCO 1.85
  • 52 Week Low
  • CAPR $5.68
  • LOCO $8.29
  • 52 Week High
  • CAPR $23.40
  • LOCO $13.93
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 54.02
  • LOCO 31.28
  • Support Level
  • CAPR $7.11
  • LOCO $9.21
  • Resistance Level
  • CAPR $8.06
  • LOCO $9.63
  • Average True Range (ATR)
  • CAPR 0.51
  • LOCO 0.19
  • MACD
  • CAPR 0.16
  • LOCO -0.06
  • Stochastic Oscillator
  • CAPR 72.64
  • LOCO 6.91

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

Share on Social Networks: